[go: up one dir, main page]

CR20140069A - Formulaciones parenterales de vacunas contra los norovirus - Google Patents

Formulaciones parenterales de vacunas contra los norovirus

Info

Publication number
CR20140069A
CR20140069A CR20140069A CR20140069A CR20140069A CR 20140069 A CR20140069 A CR 20140069A CR 20140069 A CR20140069 A CR 20140069A CR 20140069 A CR20140069 A CR 20140069A CR 20140069 A CR20140069 A CR 20140069A
Authority
CR
Costa Rica
Prior art keywords
parenteral formulations
vaccines against
against norovirus
norovirus
mixtures
Prior art date
Application number
CR20140069A
Other languages
English (en)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CR20140069A publication Critical patent/CR20140069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composiciones de vacuna parenterales de dosis individuales que comprenden mezclas de partículas tipo virus monovalentes de Norovirus. También se divulgan métodos para conferir una inmunidad protectora contra infecciones por Norovirus en un ser humano por
CR20140069A 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus CR20140069A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
CR20140069A true CR20140069A (es) 2014-06-27

Family

ID=47506489

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20190540A CR20190540A (es) 2011-07-11 2012-07-11 FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069)
CR20140069A CR20140069A (es) 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20190540A CR20190540A (es) 2011-07-11 2012-07-11 FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069)

Country Status (29)

Country Link
US (5) US9801934B2 (es)
EP (3) EP3299030B1 (es)
JP (2) JP6208659B2 (es)
KR (1) KR102096937B1 (es)
CN (3) CN108567975A (es)
AU (2) AU2012282658B2 (es)
BR (1) BR112014000656A2 (es)
CA (1) CA2841356C (es)
CL (1) CL2014000082A1 (es)
CR (2) CR20190540A (es)
DK (1) DK3299030T3 (es)
DO (2) DOP2014000004A (es)
EA (3) EA029470B1 (es)
EC (1) ECSP14013201A (es)
ES (2) ES2926487T3 (es)
GE (1) GEP201706668B (es)
HK (3) HK1198136A1 (es)
IL (1) IL230356B (es)
MA (1) MA35414B1 (es)
MX (2) MX356586B (es)
MY (1) MY170746A (es)
PE (1) PE20140845A1 (es)
PH (3) PH12014500093A1 (es)
PL (2) PL3299030T3 (es)
SG (1) SG10201605644WA (es)
TN (1) TN2014000008A1 (es)
UA (1) UA117732C2 (es)
WO (1) WO2013009849A1 (es)
ZA (2) ZA201401012B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
KR20100083150A (ko) 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
MY170746A (en) 2011-07-11 2019-08-27 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
SG10201802772YA (en) 2013-10-03 2018-05-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
EP3624851A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3752185A1 (en) * 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
WO2019231712A1 (en) * 2018-05-29 2019-12-05 Stc.Unm Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP4087604A4 (en) * 2020-01-08 2023-11-01 Bharat Biotech International Limited COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS
CA3213547A1 (en) 2021-03-29 2022-10-06 Naoshi Fukushima Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
JPH07509122A (ja) 1992-04-08 1995-10-12 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレター，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法
AU4851493A (en) 1992-09-07 1994-03-29 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
DK0757717T3 (da) 1994-05-16 2006-09-25 Merck & Co Inc Papillomavirusvacciner
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1259051A (zh) 1997-04-08 2000-07-05 麦克公司 稳定化后的人乳头瘤病毒制剂
CA2288129A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
DE69931053T2 (de) 1998-08-14 2006-11-23 Merck & Co., Inc. Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
WO2000045841A2 (en) * 1999-02-05 2000-08-10 Merck & Co., Inc. Human papilloma virus vaccine formulations
JP4629935B2 (ja) 1999-06-22 2011-02-09 国立感染症研究所長 Ｓｒｓｖ検出キット
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIO-ACTIVE MATERIALS WITH LYOPHILIZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ATE521367T1 (de) 2002-06-07 2011-09-15 Kentucky Bioproc Llc Flexlibler aufbau- und darreichungs-plattform von impfstoffen
PL375306A1 (en) 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004075829A2 (en) 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
EP1670824A2 (en) 2003-09-24 2006-06-21 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
RU2007129840A (ru) 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
AU2006224529B2 (en) 2005-03-18 2012-05-24 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008113011A2 (en) * 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
AU2008299589B2 (en) 2007-09-12 2014-06-26 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR20100083150A (ko) * 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
PL2324113T3 (pl) 2008-08-08 2018-08-31 Takeda Vaccines, Inc. Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
JP2012515752A (ja) * 2009-01-22 2012-07-12 ファーマシーネ，インコーポレイテッド 安定なワクチン組成物とその使用方法
EA201171032A1 (ru) * 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
EP2525816A4 (en) 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
MX352324B (es) * 2010-05-26 2017-11-17 Selecta Biosciences Inc Star Vacunas multivalentes de nanovehiculos sinteticos.
MY170746A (en) * 2011-07-11 2019-08-27 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
EP4253412A3 (en) 2015-12-16 2023-11-22 The Walter and Eliza Hall Institute of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
GB2605883B (en) 2016-10-18 2023-03-15 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
US20210230548A1 (en) 2018-05-03 2021-07-29 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
KR20210129105A (ko) 2019-02-15 2021-10-27 에디타스 메디신, 인코포레이티드 면역치료법을 위한 변형된 자연 살해(nk) 세포

Also Published As

Publication number Publication date
CR20190540A (es) 2022-04-04
US9867876B2 (en) 2018-01-16
ZA201401012B (en) 2015-05-27
CL2014000082A1 (es) 2014-07-04
SG10201605644WA (en) 2016-09-29
ES2926487T3 (es) 2022-10-26
KR20140066160A (ko) 2014-05-30
HK1198136A1 (en) 2015-03-13
DOP2014000004A (es) 2014-10-31
PL3299030T3 (pl) 2022-12-05
WO2013009849A1 (en) 2013-01-17
EA202090699A2 (ru) 2020-07-31
US20180185468A1 (en) 2018-07-05
GEP201706668B (en) 2017-05-25
PH12018501515B1 (en) 2022-02-18
NZ620865A (en) 2015-08-28
US20230338503A1 (en) 2023-10-26
CN103874507A (zh) 2014-06-18
JP6208659B2 (ja) 2017-10-04
JP2017214357A (ja) 2017-12-07
PH12014500093A1 (en) 2014-03-17
DOP2022000030A (es) 2022-06-30
HK1215154A1 (zh) 2016-08-19
ZA201500915B (en) 2016-06-29
EP4112074A1 (en) 2023-01-04
PE20140845A1 (es) 2014-08-03
MX356586B (es) 2018-06-05
AU2012282658B2 (en) 2014-11-27
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
CA2841356A1 (en) 2013-01-17
TN2014000008A1 (en) 2015-07-01
US20210085778A1 (en) 2021-03-25
PL2731621T3 (pl) 2018-10-31
US11701420B2 (en) 2023-07-18
UA117732C2 (uk) 2018-09-25
CA2841356C (en) 2022-03-01
EP2731621A1 (en) 2014-05-21
CN108567975A (zh) 2018-09-25
MA35414B1 (fr) 2014-09-01
DK3299030T3 (da) 2022-09-05
ECSP14013201A (es) 2014-05-31
EA201490258A1 (ru) 2014-05-30
NZ710919A (en) 2017-12-22
MX379496B (es) 2025-03-11
HK1199202A1 (en) 2015-06-26
EP3299030A1 (en) 2018-03-28
IL230356B (en) 2019-05-30
JP6613259B2 (ja) 2019-11-27
PH12021551773A1 (en) 2022-08-01
US10675341B2 (en) 2020-06-09
US20160000899A1 (en) 2016-01-07
JP2014520852A (ja) 2014-08-25
EA035442B1 (ru) 2020-06-17
MX2014000411A (es) 2014-08-26
EA201792407A2 (ru) 2018-03-30
BR112014000656A2 (pt) 2017-02-14
MY170746A (en) 2019-08-27
EP2731621B1 (en) 2017-11-01
ES2656527T3 (es) 2018-02-27
EP2731621A4 (en) 2015-03-25
EP3299030B1 (en) 2022-06-08
CN105031637A (zh) 2015-11-11
EA029470B1 (ru) 2018-03-30
EA201792407A3 (ru) 2018-07-31
AU2012282658A1 (en) 2013-03-14
EA202090699A3 (ru) 2020-11-30
KR102096937B1 (ko) 2020-04-03
PH12018501515A1 (en) 2019-02-04
AU2015200836A1 (en) 2015-03-12
AU2015200836B2 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
CR20140069A (es) Formulaciones parenterales de vacunas contra los norovirus
MX2018002728A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
PH12013502442A1 (en) Inactivated dengue virus vaccine
MY197723A (en) Vaccine compositions for the prevention of dengue virus infection
PE20151588A1 (es) Vacuna contra el virus del dengue
HK1206366A1 (en) Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
MX2015000446A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
EP2694102A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
NI201500109A (es) Vacuna polivalente de proteína de fusión contra la influenza
CR20150246A (es) Composición inmunogénica contra la aeromonas hydrophila
GT201400120A (es) Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
IN2014MN02275A (es)